ABSTRACT
OBJECTIVE: To report cases of use of chelation therapy during pregnancy which resulted in favorable outcomes for the babies. MATERIALS AND METHODS: In this retrospective cohort study, we described the evolution and outcome of 9 pregnancies in Italian thalassemic women who received deferoxamine (DFO) inadvertently during early pregnancy. RESULTS: The use of deferoxamine during first trimester did not lead to adverse effects on the fetus or cause major complications for the gestation, although an increase in iron burden was observed after suspending chelation therapy. CONCLUSION: In our experience, iron-chelation therapy might be administrated in pregnancy where the benefits to the mother outweigh the potential risks to the baby.
Subject(s)
Chelation Therapy/adverse effects , Deferoxamine/adverse effects , Maternal Exposure/adverse effects , Pregnancy Complications, Hematologic/drug therapy , Siderophores/adverse effects , beta-Thalassemia/drug therapy , Adult , Deferoxamine/administration & dosage , Female , Humans , Live Birth , Maternal-Fetal Exchange/drug effects , Pregnancy , Pregnancy Trimester, First , Retrospective Studies , Siderophores/administration & dosageABSTRACT
In this study, we compared the long-term effects of different iron chelation regimens (deferoxamine, deferiprone, deferoxamine + deferiprone, and deferasirox) in preventing or reversing endocrinopathy (diabetes mellitus, hypothyroidism, or hypogonadism) and bone disease (measured through DEXA) in 165 adults with ß-thalassemia major (TM) (mean age 39.9 ± 8.3 years, 43 % males). After five consecutive years of therapy, patients on deferasirox had the highest decrease in the prevalence of any endocrinopathy compared to other chelators which either had no change (deferiprone and deferoxamine) or had an increase (deferoxamine + deferiprone), p = 0.015. This was attributed to a lower proportion of patients on deferasirox developing new-onset endocrinopathy and higher proportion showing reversal of disease, compared to other chelators. A serum ferritin level of >1300 ng/mL predicted the development of new endocrinopathy (p = 0.025) while a level of <200 ng/mL predicted reversal of existing endocrinopathy (p = 0.147). A significant increase in mean BMD T-score (p < 0.001) and a considerable decrease in osteoporosis prevalence were observed in patients receiving deferasirox but not other chelators. Iron chelation therapy with deferasirox has a role in the prevention of endocrinopathy and reversal of existing disease.
Subject(s)
Chelation Therapy , Iron Chelating Agents/therapeutic use , beta-Thalassemia/therapy , Adult , Benzoates/therapeutic use , Deferasirox , Deferiprone , Deferoxamine/therapeutic use , Diabetes Mellitus/etiology , Diabetes Mellitus/prevention & control , Drug Therapy, Combination , Female , Follow-Up Studies , Humans , Hypogonadism/etiology , Hypogonadism/prevention & control , Hypothyroidism/etiology , Hypothyroidism/prevention & control , Iron Overload/complications , Iron Overload/drug therapy , Male , Middle Aged , Osteoporosis/etiology , Osteoporosis/prevention & control , Prevalence , Pyridones/therapeutic use , Retrospective Studies , Transfusion Reaction , Triazoles/therapeutic use , beta-Thalassemia/complicationsABSTRACT
Splenectomized patients are exposed to an increased risk of septicemia caused by encapsulated bacteria. Defense against infection is ensured by preformed serum antibodies produced by long-lived plasma cells and by memory B cells that secrete immunoglobulin in response to specific antigenic stimuli. Studying a group of asplenic individuals (57 adults and 21 children) without additional immunologic defects, we found that spleen removal does not alter serum anti-pneumococcal polysaccharide (PnPS) IgG concentration, but reduces the number of PnPS-specific memory B cells, of both IgM and IgG isotypes. The number of specific memory B cells was low in splenectomized adults and children that had received the PnPS vaccine either before or after splenectomy. Seven children were given the 13-valent pneumococcal conjugated vaccine after splenectomy. In this group, the number of PnPS-specific IgG memory B cells was similar to that of eusplenic children, suggesting that pneumococcal conjugated vaccine administered after splenectomy is able to restore the pool of anti-PnPS IgG memory B cells. Our data further elucidate the crucial role of the spleen in the immunological response to infections caused by encapsulated bacteria and suggest that glycoconjugated vaccines may be the most suitable choice to generate IgG-mediated protection in these patients.
Subject(s)
B-Lymphocyte Subsets/immunology , Immunologic Memory , Pneumococcal Infections/immunology , Spleen/immunology , Splenectomy , Vaccination/methods , Adolescent , Adult , Aged , Aged, 80 and over , Antibodies, Bacterial/blood , Antigens, Bacterial/immunology , Child , Child, Preschool , Female , Humans , Immunoglobulin G/blood , Infant , Male , Middle Aged , Pneumococcal Infections/prevention & control , Pneumococcal Vaccines/administration & dosage , Polysaccharides, Bacterial/immunology , Tetanus/immunology , Young AdultSubject(s)
Immunologic Factors/administration & dosage , Purpura, Thrombocytopenic, Idiopathic/therapy , Rho(D) Immune Globulin/administration & dosage , Adolescent , Child , Child, Preschool , Chronic Disease , Female , Humans , Male , Methylprednisolone/administration & dosage , Platelet Count , Purpura, Thrombocytopenic, Idiopathic/bloodABSTRACT
Venous thrombosis of transverse and sigmoid sinuses was diagnosed in a 3-year-old child who is a carrier of the G20210A prothrombin gene mutation. Recombinant tissue plasminogen activator (rt-PA) treatment was started 9 days following the onset of neurologic signs. Nine days of rt-PA therapy completely dissolved the thrombus. This case provides further evidence that rt-PA is useful and safe in children with thrombosis.
